FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo
Open Access
- 28 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1) , e55034
Abstract
The molecular mechanisms that are involved in the growth and invasiveness of osteosarcoma, an aggressive and invasive primary bone tumor, are not fully understood. The transcriptional co-factor FHL2 (four and a half LIM domains protein 2) acts as an oncoprotein or as a tumor suppressor depending on the tissue context. In this study, we investigated the role of FHL2 in tumorigenesis in osteosarcoma model. Western blot analyses showed that FHL2 is expressed above normal in most human and murine osteosarcoma cells. Tissue microarray analysis revealed that FHL2 protein expression is high in human osteosarcoma and correlates with osteosarcoma aggressiveness. In murine osteosarcoma cells, FHL2 silencing using shRNA decreased canonical Wnt/β-catenin signaling and reduced the expression of Wnt responsive genes as well as of the key Wnt molecules Wnt5a and Wnt10b. This effect resulted in inhibition of osteosarcoma cell proliferation, invasion and migration in vitro. Using xenograft experiments, we showed that FHL2 silencing markedly reduced tumor growth and lung metastasis occurence in mice. The anti-oncogenic effect of FHL2 silencing in vivo was associated with reduced cell proliferation and decreased Wnt signaling in the tumors. Our findings demonstrate that FHL2 acts as an oncogene in osteosarcoma cells and contributes to tumorigenesis through Wnt signaling. More importantly, FHL2 depletion greatly reduces tumor cell growth and metastasis, which raises the potential therapeutic interest of targeting FHL2 to efficiently impact primary bone tumors.Keywords
This publication has 54 references indexed in Scilit:
- Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcomaMolecular Medicine Reports, 2012
- FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancerLaboratory Investigation, 2011
- The Wnt signaling pathway: implications for therapy in osteosarcomaExpert Review of Anticancer Therapy, 2011
- FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cellsCancer Letters, 2011
- The role of WNT10B in physiology and diseaseActa Physiologica, 2011
- Wnt5a: its signalling, functions and implication in diseasesActa Physiologica, 2011
- High Wnt Signaling Represses the Proapoptotic Proteoglycan syndecan-2 in Osteosarcoma CellsCancer Research, 2010
- Deficiency of the LIM-Only Protein FHL2 Reduces Intestinal Tumorigenesis in Apc Mutant MicePLOS ONE, 2010
- Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain proteinHuman Molecular Genetics, 2000
- FHL2, a novel tissue‐specific coactivator of the androgen receptorThe EMBO Journal, 2000